Saghmos Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Saghmos Therapeutics, Inc., a biopharmaceutical company based in Greenwich, Connecticut, has announced its upcoming participation in the Goldman Sachs 45th Annual Global Healthcare Conference. Saghmos, which is privately held, is preparing to advance ST-62516 (trimetazidine) into a Phase 3 clinical trial aimed at mitigating cardiorenal complications following percutaneous coronary interventions (PCI).

Dr. Anna Kazanchyan, the Founder and CEO of Saghmos, is slated to present at the conference on June 12th at 3:20 PM Eastern Time. The presentation will be broadcast live via webcast, and a replay will be available shortly after the session.

Saghmos Therapeutics is developing ST-62516, a cardiorenal metabolic modulator designed to lower the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) following contrast procedures such as PCI. Each year, over a million PCI procedures are conducted in the United States on patients suffering from unstable angina or heart attacks. About half of these patients present with comorbidities that increase the procedural risk. Currently, there are no FDA-approved drugs specifically targeting the prevention or treatment of AKI and MACKE, highlighting a significant unmet medical need.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!